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a b s t r a c t 
Background: Recent works present evidence of Propionibacterium acnes growing as a bioﬁlm in cutaneous 
follicles. This formation of clusters is now considered as an explanation for the in vivo resistance of P. 
acnes to the main antimicrobials prescribed in acne vulgaris. 
Purpose: Our objective was to explore this hypothesis and propose a new therapeutic approach focusing 
on anti-bioﬁlm activity of Myrtacine ® New Generation (Mediterranean Myrtle extract–Botanical Expertise 
P. Fabre) alone or combined with antibiotics. 
Methods/Results: Using in vitro models able to promote the growth of adhered bacteria, the loss of sen- 
sitivity of P. acnes bioﬁlms (48 h) towards erythromycin and clindamycin was checked considering either 
sensitive or resistant strains. In the same time, the activity of Myrtacine ® New Generation against bioﬁlm 
formation and mature bioﬁlm (48 h) was evaluated. Using a dynamic model of bioﬁlm formation, we 
noted an inhibition of bioﬁlm formation (addition of Myrtacine ® New Generation at T 0) and a signiﬁcant 
effect on mature bioﬁlm (48 h) for 5 min of contact. This effect was also checked using the static model 
of bioﬁlm formation for Myrtacine ® New Generation concentrations ranging from 0.03% to 0.0 0 01%. A 
signiﬁcant, dose-dependent anti-bioﬁlm effect was observed and notable even at a concentration lower 
than the active concentration on planktonic cells, i.e. 0.001%. Finally, the interest of the combination of 
Myrtacine ® New Generation with antibiotics was explored. An enhanced eﬃcacy was noted when ery- 
thromycin (10 0 0 mg/l) or clindamycin (50 0 mg/l) was added to 0.0 01% Myrtacine ®, leading to signiﬁcant 
differences in comparison to each compound used alone. 
Conclusion: The eﬃciency of Myrtacine ® New Generation on P. acnes bioﬁlm alone or combined with 
antibiotics was demonstrated and can lead to consider it as a potent adjunctive product eﬃcient during 
the antibiotic course for acne vulgaris treatment. 
© 2016 The Authors. Published by Elsevier GmbH. 
This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ). 
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Propionibacterium acnes is a Gram positive bacillus that is part
f the human ecosystems ( Grice and Segre 2011 ). P. acnes resides
n pilosebaceous follicles of the skin, colonizing the lipid-rich seba-
eous glands. As an opportunist, P. acnes is well recognized as be-
ng involved in the inﬂammation process of acne vulgaris ( Burkhart
nd Gottwald 2003; Li et al. 2014 ), a common skin disorder that∗ Corresponding author. Tel.: +33 5 62 25 68 60; fax: +33 5 61 25 95 72. 
E-mail address: ch.roques@wanadoo.fr , roques730@aol.com (C. Roques). 
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hronic diseases. More recently, it has become recognized as the
ause of foreign-body infections ( Portillo et al. 2013 ) by devices
uch as breast implants ( Del Pozo et al. 2009 ), neurosurgical shunts
 Conen et al. 2008 ), cardiovascular devices ( Delahaye et al. 2005 ),
cular implants, internal fracture ﬁxation devices, spinal hardware,
nd prosthetic joints ( Levy et al. 2013; Piper et al. 2009; Portillo
t al. 2013 ). 
At ﬁrst, P. acnes was considered to be susceptible to a
ide range of antibiotics, including clindamycin, ß-lactams and
uinolones ( Hoeﬄer et al. 1976 ). However, in the last decade, the
ate of antibiotic-resistant bacteria has increased, especially fore under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ). 
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o  macrolides and tetracyclines ( Dumont-Wallon et al. 2010; Ozolins
et al. 2004 ) but also rifampicin ( Furustrand Taﬁn et al. 2015 ).
Although P. acnes virulence is reported to be low, recent studies
using genomic approaches and in situ observations have allowed a
better understanding of this pathogen’s importance in chronic and
recurrent infections, focusing on the ability of P. acnes to produce a
bioﬁlm on implant devices ( Holmberg et al. 2009 ), and also in acne
( Jahns and Alexeyev 2014; Jahns et al. 2012 ). The loss of sensitiv-
ity of microorganisms in a bioﬁlm to the main antimicrobials could
explain both treatment failures and the fact that no optimal treat-
ment regimen of P. acnes bioﬁlm infections has yet been deﬁned, in
either implant-associated infections ( Furustrand Taﬁn et al. 2015 )
or acne ( Coenye et al. 2007 ). 
In 2009, James et al. reviewed the current acne treatments,
and underlined signiﬁcant side effects of isotretinoin and rising
antibiotic resistance ( James et al. 2009 ). Recent advances in the
pathogenesis of acne and inﬂammatory mechanisms and the
role of P. acnes as bioﬁlms led to new targets being considered.
New molecules with potent P. acnes anti-bioﬁlm eﬃcacy were
thus investigated. Some plant extracts or their active components
have already been described as anti-bioﬁlm even at subinhibitory
concentrations ( Coenye et al. 2012 ). Studies of the pharmacological
properties of Myrtus communis L. (Myrtaceae) demonstrated its
antibacterial eﬃciency against P. acnes strains that may be linked
to myrtucommulones ( Alipour et al. 2014; Fiorini-Puybaret 2011 ). 
The present study continues along these lines by studying the
eﬃcacy of an isopropyl acetate extract prepared from leaves of M.
communis (Myrtacine ® New Generation), previously demonstrated
to be effective on P. acnes planktonic cells ( Alipour et al. 2014;
Fiorini-Puybaret 2011 ), in combating P. acnes bioﬁlm. For this pur-
pose, we validated in vitro bioﬁlm models (dynamic or static) in
which growth of adherent P. acnes , but not of planktonic cells,
was promoted. Myrtacine ® New Generation was tested alone or
in combination with the most current topical antibiotics used in
acne treatment (erythromycin and clindamycin). The interest of
this extract and its association with antibiotics was checked on P.
acnes strains presenting sensitivity or acquired resistance to ery-
thromycin and clindamycin. 
Materials and methods 
Plant material 
Leaves of M. communis were collected in Morocco in 2008 (Re-
gion around Fes). Identiﬁcation of this plant was conﬁrmed by
Dr. Jean Gabriel Fouche (Institut de Recherche Pierre Fabre). A
voucher specimen (N °16280) has been deposited at the Conserva-
toire Botanique Pierre Fabre, (Cambounet-sur-Sor, France). 
Extraction 
Myrtacine ® New Generation is a lipophilic dry extract from
leaves of M. communis produced by the Pierre Fabre Company
( Fiorini-Puybaret 2011 ). It was prepared from dried powdered
leaves using isopropyl acetate (ratio 1:10) at room temperature for
2 h. After ﬁltration, the residue was treated a second time using
the same method and the two fractions were pooled. After the
removal of chlorophyll using activated charcoal (1% w/w) and es-
sential oil by hydro-distillation, the ﬁltrate was concentrated un-
der vacuum at 40 °C. The residue was resuspended in water then
dried by lyophilisation. Myrtacine ® New Generation was obtained
as a yellow powder with a yield of 2% w/w. The extract was stored
in the dark at 4 °C. 
The aqueous solutions tested were prepared extemporaneously
with dimethylsulphoxide (maximum concentration 10%). uantiﬁcation of the ursolic acid and the myrtucommulones 
HPLC analyses were carried out on a Merck/Hitachi LaChrom
PLC system comprising a L7420 PDA detector and a L7200
ump. Myrtucommulones B ´ (5-déméthylsemimyrtucommulone)
 (semimyrtucommulone), IsoS (isosemimyrtucommulone), A
myrtucommulone A) and ursolic acid were titrated by analytical
PLC performed with a column Symmetry ® C8 (Waters), 5 μm,
45 mm x 4.6 mm using a gradient with 0.1% aqueous triﬂuo-
oacetic acid 0.1% (eluent A) and a mixture of acetonitrile and
riﬂuoroacetic acid 0.1% (eluent B) with the following program:
 min: 78% B; 15–25 min: 100% B; 26–35 min: 78% B. Spectral UV
ata from the peaks were accumulated in the range 210–400 nm.
etection with the diode array was performed at 280 nm for
yrtucommulones and 210 nm for ursolic acid. The temperature
f the column was maintained at 20 ± 5 °C. The ﬂow rate of
he mobile phase was 1 ml/min. The injection volume was 10 μl
nd the samples were prepared in the mixture dichloromethane-
thanol: 1-1 (v/v). 2-methylanthraquinone (2-MAQ) was used as
n external standard. The response factor of the myrtucommulone
’ (3.1) and ursolic acid (12.7) relative to the 2-MAQ were deﬁned
ith pure myrtucommulone B’ and ursolic acid previously puriﬁed
unpublished work). Using these response factors the respective
esponse factors of ursolic acid and myrtucommulones relative to
yrtucommulone B’ in the extract were calculated. Under these
onditions the 2-methylanthraquinone, ursolic acid, myrtucommu-
ones B’, S, IsoS and A were eluted at 5.3 min, 9.9 min, 9.3 min,
0.4 min, 11.1 min and 21.9 min respectively (Suppl. Figs. 1 and 2,
upplementary content). Myrtucommulones and ursolic acid were
uantiﬁed by HPLC. Their contents in the batch ES 120 used for
his study were respectively 8.1% (w/w) and 20% w/w. 
ntibiotics 
Erythromycin and clindamycin were obtained from Sigma
ldrich (Saint-Quentin Fallavier, France) and were dissolved in
thanol (5% ﬁnal maximum concentration) or water respectively. 
inimal medium for bioﬁlm formation 
In preliminary studies ( Khalilzadeh et al. 2010; Samrakandi
t al. 1997 ), we demonstrated that MBB (Modiﬁed Bioﬁlm Broth)
as able to promote the growth of adherent cells but not of
lanktonic ones. The selected minimal medium consisted of MgSO 4 
H 2 O (0.2 g/l), FeSO 4 7H 2 O (0.0 0 05 g/l), anhydrous Na 2 HPO 4 
1.25 g/l), KH 2 PO 4 (0.5 g/l), (NH 4 ) 2 SO 4 (0.1 g/l) and glucose
0.05 g/l). The ability of P. acnes to form a bioﬁlm using this
edium was checked in dynamic and static models. 
election of P. acnes strains 
Reference strains (Institute Pasteur Collection, Paris, France) and
utaneous isolates (24 strains) from the lab collection and Pierre
abre DermoCosmetics collection were screened for their suscepti-
ility to erythromycin and clindamycin as planktonic cells. Strains
ere preserved in Eugon broth complemented with 10% glycerol
t –80 °C. Before each experiment, two subcultures on Columbia
heep blood agar (bioMérieux, Craponne, France) were performed
or 48 h at 36 °C, under anaerobic conditions (Anoxomat Mart
ystem, Mart Microbiology B.V., Netherlands). MICs were deter-
ined by a broth dilution micromethod according to EUCAST and
ASFM recommendations ( www.sfm-microbiologie.org ). Brieﬂy,
olutions under assay were diluted in microtitre plates in Mueller
inton broth (bioMérieux, Craponne, France) supplemented by 10%
oetal bovine serum (Dutscher, Brumath, France) to a ﬁnal volume
f 100 μl. Microbial suspensions were prepared in tryptone salt
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Table 1 
MIC/MBC values (mg/l) of erythromycin and clindamycin 
for the selected strains. 
Erythromycin Clindamycin 
MIC MBC MIC MBC 
P. acnes CIP 53.117T 0.016 0.016 0.03 0.03 
P. acnes CIP 110.371 > 500 > 500 2 2 
P. acnes B872 0.008 0.008 0.03 0.03 
P. acnes R4 > 500 > 500 62.5 62.5 
P. acnes R3.6 > 500 > 500 62.5 62.5 olution at about 10 8 CFU/ml to obtain ﬁnal inocula of 10 6 CFU/ml
n wells. Microtitre plates were incubated for 48 h at 36 °C, under
naerobic conditions. The MIC was then deﬁned as the concentra-
ion at which no macroscopic sign of cellular growth was detected
n comparison with the control without antimicrobial compound
column 12). Column 11 was free of inoculum and checked the
terility conditions. The MBCs were determined by sub-cultivating
n Columbia sheep blood agar plates after incubating as described
bove. The MBC was deﬁned as the compound concentration at
hich no macroscopic sign of cellular growth was detected in
omparison to the control without antimicrobial compound. 
All the experiments were carried out in duplicate at each con-
entration. In order to ensure that dimethylsulphoxide and ethanol
er se did not interfere with the antimicrobial activity of the prod-
cts under assay, a control test was also carried out on inoculated
roth supplemented with only dimethylsulphoxide and ethanol at
he same concentration used in the assays. 
actericidal activity on planktonic cells in MBB 
To assess the bactericidal activity of Myrtacine ® New Genera-
ion (0.03% to 0.0 0 01% w/v) and antibiotics (erythromycin: 0.1 mg/l
o 10 0 0 mg/l; clindamycin: 10 mg/l to 500 mg/l) on non-growing
lanktonic cells in MBB, 10 5 CFU/ml were maintained under ag-
tation (100 rpm) and anaerobic conditions at 36 °C for 72 h in
he presence or absence of each product. Cell quantiﬁcation was
arried out by culture of samples (24 h, 48 h and 72 h). The sam-
les were homogenized and serially diluted (10-fold dilutions), and
00 μl of each dilution were spread on Columbia sheep blood agar
nd incubated at 36 °C under anaerobic conditions for 5 days. 
ioﬁlm formation 
ynamic model 
P. acnes bioﬁlms were obtained by a previously described pro-
edure ( Samrakandi et al. 1997 ). The MBB was circulated through a
terile loop of Tygon ® tube (Fischer Scientiﬁc SAS, Illkirch, France,
nner diameter, 6.4 mm) at 100 ml/min. The loop was maintained
t 30 °C and was connected to a discharge line and to a feeding
ank (supply pump; feeding rate, 3 ml/min). After the bioreactor
ad been ﬁlled with the adhesion broth, the loop was inoculated
ith 5 ml of a bacterial suspension containing about 10 8 CFU/ml.
he circulation pump was run for 30 min to allow the cells to
pread around the loop before the supply pump was turned on. Af-
er 48 h, stabilized and reproducible populations of adherent and
vacuated bacteria were obtained for the tested strain. 
The adherent cells were recovered by scraping them off samples
f the Tygon tube (2-cm pieces cut in half lengthwise) with a ster-
le cutter in 10 ml distilled water. The portions of the Tygon tube
nd the corresponding suspension were then dispersed for 1 min
ith a vortex mixer. Viable bacterial counts (log CFU/cm 2 ) were
etermined by spreading of duplicate serial dilutions of homoge-
ized samples on Columbia sheep blood agar. The agar plates were
ncubated anaerobically as described above. Results are expressed
s log CFU/cm 2 and the quantiﬁcation limit was considered to be
.4 log. Planktonic population was also evaluated. 
tatic model 
Bacterial suspensions of the tested strains were prepared and
iluted in each tested medium in order to obtain a concentra-
ion of either 10 5 CFU/ml. Two millilitres of bacterial suspensions
ere added to the wells of 24-well polystyrene microplates (BD
alcon, San Jose, CA, USA). Microplates were incubated statically
t 36 °C (to check P. acnes optimal culture and in vivo condi-
ions), under anaerobiosis. During the course of incubation and
hen products were added, the medium was renewed, after twoentle rinses, in order to eliminate non-adherent/released bacte-
ia from the bioﬁlm and favour sessile growth. Before bioﬁlm col-
ection, planktonic cells were sampled by pipetting directly in the
ulk phase. After two successive rinses with 2 ml of sterile distilled
ater (SDW), 1 ml of SDW was added and the well was scraped
ith a sterilized spatula for 1 min in order to detach bioﬁlm cells.
umerations of viable cells (adherent and planktonic) were per-
ormed as previously described. Results are expressed as log CFU
er well and the quantiﬁcation limit was considered to be 1.3 log. 
ioﬁlm treatments 
Myrtacine ® New Generation concentrations were selected ac-
ording to the maximum concentration in the marketed product
nd were between 0.1% and 0.0 0 01% (w/v). 
Antibiotic concentrations were deﬁned by considering MIC/MBC
alues and lack of bactericidal activity on planktonic cells in MBB,
.e. erythromycin: 10 0 0 and 50 0 mg/l for erythromycin resistant
trains and 10 and 0.1 mg/l for erythromycin sensitive strains and
0 0, 10 0 and 10 mg/l for clindamycin. 
Myrtacine ® New Generation was ﬁrst evaluated for (i) pre-
entive treatment, which consisted of an addition of the prod-
ct (0.001%, 0.01% and 0.1% w/v) at the time of inoculation of
he dynamic bioﬁlm model (T 0) and numeration of adherent and
lanktonic cells at 5 h, 24 h and 48 h and (ii) curative treat-
ent, which consisted of an addition of the product (0.1%, 0.01%
nd 0.001% w/v) on a 48 h bioﬁlm with circulation for 1 min and
 min. 
To explore the anti-bioﬁlm activity of Myrtacine ® New Genera-
ion and the interest of using it in association with antibiotics, we
onsidered a treatment consisting of an addition of the products
Myrtacine ® New Generation associated or not with antibiotics) to
 48 h bioﬁlm for 24 h of contact using the static model. 
tatistical analysis 
Comparisons between data sets were performed using paired
 -test and signiﬁcant differences were deﬁned for p < 0.05 and
 < 0.01. 
esults 
election of P. acnes strains 
Table 1 presents the MICs and MBCs for the selected cutaneous
solates and the reference strains showing their level of suscep-
ibility to erythromycin and clindamycin. P. acnes CIP 53.117T is
ensitive to both molecules. P. acnes CIP 110.371 is described as
esistant to erythromycin and also presents reduced susceptibil-
ty to clindamycin. Among wild cutaneous strains, the selection
ncludes a sensitive strain (B872), and two strains characterized
y resistance to erythromycin and clindamycin (R4 and R3.6). No
310 C. Feuillolay et al. / Phytomedicine 23 (2016) 307–315 
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Control
Myrtacine 0.03%
Myrtacine 0.01%
Myrtacine 0.001%
Myrtacine 0.0001%
**
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**
**
**
**
**
**
Fig. 1. Evaluation of bactericidal activity (log CFU/ml) of Myrtacine ® new generation against planktonic eryS/clindaS (CIP 53.117T; B872) and eryR/clindaR (CIP 110.371; R4) 
strains in MBB according to the contact time (T 0 to T 72 h). 
∗∗: p < 0.01. 
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Control erythromycin 
1000 mg/l
erythromycin          
500 mg/l
erythromycin           
10 mg/l
erythromycin            
0.1 mg/l
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CIP 53.117T
B872
R4
**
ND ND ND
Fig. 2. Evaluation of bactericidal activity (log CFU/ml) of erythromycin against planktonic eryS (CIP 53.117T and B872) and eryR (R4) strains in MBB after 24 h of contact. 
ND, not determined. 
∗∗, p < 0.01. 
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at the highest ﬁnal concentrations used (data not shown). 
Bactericidal activity on planktonic cells in MBB 
P. acnes strains were exposed to Myrtacine ® (from 0.0 0 01 to
0.03%) for 72 h. The evolution of bacterial concentrations accord-
ing to the contact time and the Myrtacine ® New Generation con-
centration in MBB is indicated in Fig. 1 . A bactericidal effect can
be noted starting from 24 h of contact with the highest concentra-
tions (0.03%, 0.01% and 0.001% w/v). At 0.001% (w/v), a signiﬁcant
time-dependent reduction is observed but no clearance expected
for P. acnes B872. The initial planktonic P. acnes population was
preserved in the presence of 0.0 0 01% Myrtacine ® New Generation
even after a 72 h of contact. Most importantly similar behaviours
were observed among strains, regardless of their susceptibility
to erythromycin or clindamycin according to MIC/MBC ( Table 1 )
determination. 
When strains were in contact with erythromycin in MBB for
24 h at 10 or 0.1 mg/l ( Fig. 2 ), no bactericidal activity was
noted even for susceptible strains (MBC ≤ 0.016 mg/l) while the
10 0 0 mg/l concentration led to a total reduction of the strains. For
the R4 resistant strain, no bactericidal effect was detected, even at
the 10 0 0 mg/l concentration. 
Clindamycin had no bactericidal effect on the tested strains
even at 500 mg/l ( Fig. 3 ) and even on susceptible strains in the
assay conditions. The preservation of P. acnes viability in MBB without cell pro-
iferation was demonstrated by the CFU values for the control
 Figs. 1–3 ). 
nti-bioﬁlm activity 
ynamic model 
ctivity of Myrtacine ® New Generation from the adhesion step.
ig. 4 presents the CFU numeration of adherent cells/cm 2 ( P. ac-
es CIP 53.117T) when Myrtacine ® New Generation (0.1%, 0.01% or
.001% w/v) was added or not at T 0 in the broth medium. In such
onditions, Myrtacine ® New Generation induced a dose-dependent
nti-bioﬁlm effect decreasing from 0.1% to 0.001%, with no signif-
cant effect at the lowest concentration. This effect was also time-
ependent, with a signiﬁcant increase of activity from 24 h to 48 h
f contact (0.1% and 0.01% w/v). At high Myrtacine ® New Genera-
ion concentrations, a signiﬁcant reduction in planktonic cells (cells
eleased from the bioﬁlm), of about 2 to 3 log, was also observed
data not shown). 
ctivity of Myrtacine ® New Generation on a mature bioﬁlm. As-
ays were performed on a 48 h P. acnes CIP 53.117T bioﬁlm.
yrtacine ® New Generation contact was achieved by the addition
nd circulation of solutions for 1 min and 5 min. After rinsing,
he residual adherent cells were counted ( Fig. 5 ). We observed a
igniﬁcant dose-range effect leading to a global reduction of the
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Control clindamycin         
500 mg/l
clindamycin         
100 mg/l
clindamycin            
10 mg/l
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CIP 53.117T
CIP 110.371
R3.6
Fig. 3. Evaluation of bactericidal activity (log CFU/ml) of clindamycin against planktonic clindaS (CIP 53.117T) and clindaR (CIP 110.371 and R3.6) strains in MBB after 24 h 
of contact. 
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5.4
Control Myrtacine 0.1% Myrtacine 0.01% Myrtacine 0.001%
Lo
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U
/c
m
2
5h
24h
48h
** **
** *
NR NR
Fig. 4. Number of adherent cells (log CFU/cm 2 ; n = 2; mean ± SD) when Myrtacine ® new generation is added for T 0 ( P. acnes CIP 53.117T, dynamic model) according to 
the contact time (5 h, 24 h and 48 h) and the concentration (0.1%, 0.01% and 0.001%). 
NR, no recovery. 
∗ p < 0.05 ∗∗p < 0.01. 
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Myrtacine 0.1%
Myrtacine 0.05%
Myrtacine 0.01%
Myrtacine 0.001%
**
Fig. 5. Number of residual adherent cells (log CFU/cm 2 ; n = 2; mean ± SD) after treatment of a 48 h bioﬁlm ( P. acnes CIP 53.117T; dynamic model) with Myrtacine ® new 
generation according to the contact time (0 mn, 1 mn and 5 mn) and the concentration (0.1%, 0.01% and 0.001%). SDW = control. 
∗∗ p < 0.01. 
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e  dherent population at the highest concentration 0.1% (w/v) com-
ared to the control (addition and circulation of sterile distilled
ater only). 
tatic model 
yrtacine ® New Generation anti-bioﬁlm activity. In static condi-
ions, assays were performed by the introduction of Myrtacine ®
ew Generation (0.03%, 0.01%, 0.001% and 0.0 0 01% w/v) on a ma-ure bioﬁlm (48 h old) with a contact time of 24 h. In such con-
itions, a signiﬁcant dose-dependent effect was observed, greater
ith the dynamic model, with a progressive loss of activity to
he 0.0 0 01% (w/v) concentration ( Fig. 6 ). The assay was performed
n 4 different strains and revealed similar behaviour regardless of
heir susceptibility to erythromycin and clindamycin. A total reduc-
ion of the planktonic viable population was noted at the high-
st concentrations tested (0.03% and 0.01% w/v, data not shown),
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Fig. 6. Number of residual adherent cells (log CFU per well) for 4 P. acnes strains ( P. acnes CIP 53.117T eryS/clindaS; P. acnes B872 eryS/clindaS; P. acnes CIP 110.371 
eryR/clindaR; P. acnes R4 eryR/clindaR) after addition of Myrtacine ® new generation (0.03%, 0.01%, 0.001% and 0.0 0 01%) on a 48 h bioﬁlm for a 24 h contact (static model). 
∗∗, p < 0.01. 
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C  in correlation with our previous results on planktonic cells in
MBB ( Fig. 1 ). This bactericidal effect decreased from 0.01% to
0.0 0 01% (w/v). 
Myrtacine ® New Generation anti-bioﬁlm activity when combined with
antibiotics. 
Myrtacine ® New Generation + erythromycin. Assays were per-
formed as indicated above, with a contact time of 24 h on a ma-
ture bioﬁlm (48 h) for P. acnes CIP 53.117T ( Fig. 7 a) and P. acnes CIP
110.371 ( Fig. 7 b). The ﬁrst observation was a dramatic loss of bac-
tericidal activity of erythromycin alone on P. acnes bioﬁlm regard-
less of the susceptibility of planktonic cells to erythromycin (MICs),
with little or no reduction of adherent cells even at 10 0 0 mg/l. The
difference between susceptible and resistant strains was seen only
on the planktonic population for the resistant strain ( P. acnes CIP
110.371), signiﬁcantly higher that for the sensitive strain. 
To detect a possible interaction between Myrtacine ® New Gen-
eration and antibiotic, solutions of Myrtacine ® New Generation
(0.001 % and 0.0001 % (w/v)) were added to the bioﬁlm after 48 h
of bioﬁlm formation for a 24 h contact time. When Myrtacine ®
New Generation was added to erythromycin at 10 0 0 mg/l, a sig-
niﬁcant reduction of the sessile population was noted in compari-
son to each product alone, to a supplementary reduction of about
1.5 to 2 log. This effect concerned the 0.001% Myrtacine ® concen-
tration and also the 0.0 0 01% one, which was considered as a non-
active concentration when Myrtacine ® New Generation was tested
alone. This high enhancement of activity was also signiﬁcant on
the planktonic population, with detection of viable cells for the re-
sistant strain ( P. acnes CIP 110.371: Fig. 7 b) and no detection for
the susceptible strain ( P. acnes CIP 53.117T: Fig. 7 a). 
Myrtacine ® New Generation + clindamycin. Following the same
experiments, sessile P. acnes was exposed to clindamycin in combi-
nation with Myrtacine ® New Generation. Both sensitive and resis-
tance strains ( Fig. 8 a) CIP 53.117T and (8b) CIP 110.371 were very
resistant to clindamycin alone (500 mg/l) even on the planktonic
population (more than 3 log CFU per well after treatment). This
last observation conﬁrmed previous results on planktonic cells in
MBB ( Fig. 3 ). When Myrtacine ® New Generation 0.001% (w/v) was
combined with clindamycin, we observed a marked improvement
in anti-bioﬁlm activity (reduction gain 1.5 log) on both strainsith little or no detection of residual planktonic cells. For the
.0 0 01%/50 0 mg/l association, the effect was not higher than that
f each product alone. 
iscussion 
P. acnes is frequently considered as highly susceptible to a wide
ange of antibiotics, including β-lactams, quinolones, macrolides,
lindamycin and rifampicin, even if its resistance is increasing,
specially to clindamycin and erythromycin. At the moment,
nfections linked to this opportunistic pathogen, such as invasive
nfections associated with implants but also acne vulgaris , require
rolonged antibiotic treatment ( Achermann et al. 2014 ) without
uaranty of eﬃciency. Among the virulence factors described, the
bility of P. acnes to form bioﬁlm has recently been considered as a
ajor explanation for antibiotic susceptibility loss and implicated
n the inﬂammation process ( Li et al. 2014 ). P. acnes bioﬁlm for-
ation in follicles is actually well described in healthy subjects as
ell as in those with acne vulgaris ( Jahns and Alexeyev 2014 ) with
 higher prevalence for the last group ( Jahns et al. 2012 ). In such
onditions, the main antimicrobial treatment in acne vulgaris, in-
luding erythromycin, tetracyclines, clindamycin, and also salicylic
cid or benzoyl peroxide were described as being unable to totally
educe P. acnes bioﬁlm in vitro ( Coenye et al. 2007 ). The present
esults conﬁrm the low activity of erythromycin and clindamycin
n P. acnes bioﬁlm even at high concentrations, leading to similar
eduction of bioﬁlm populations regardless of the strain suscep-
ibility deﬁned by MIC determination. Assays performed on MBB
onﬁrmed that, in conditions that prevent planktonic cell prolif-
ration, clindamycin has no bactericidal effect, even on sensitive
trains and at high concentration (500 mg/l). Similar observations
ave been reported by Furustrand Taﬁn et al. (2012) with low MICs
ut high MBCs underlying the only bacteriostatic effect of clin-
amycin and low activity on P. acnes bioﬁlm. Besides, erythromycin
s effective at 10 0 0 mg/l but only against sensitive strains. Despite
ifferences between the two antibiotics bactericidal effect on
on-growing cells, P. acnes bioﬁlms are always resistant. These
esults are in accordance with previous experiments performed by
oenye et al. (2007 ) using microtitre plate crystal violet assay. The
C. Feuillolay et al. / Phytomedicine 23 (2016) 307–315 313 
a
b
1.30
1.80
2.30
2.80
3.30
3.80
4.30
4.80
5.30
5.80
Control Erythromycin 
1000 mg/l
Myrtacine 
0.001%
Myrtacine 
0.0001%
Erythromycin 
1000 mg/l + 
Myrtacine 
0.001%
Erythromycin 
1000 mg/l + 
Myrtacine 
0.0001%
Lo
g 
CF
U
 p
er
 w
el
l
Sessile cells Planktonic cells**
**
**
*
1.30
1.80
2.30
2.80
3.30
3.80
4.30
4.80
5.30
5.80
Control Erythromycin 
1000 mg/l
Myrtacine 
0.001%
Myrtacine  
0.0001%
Erythromycin 
1000 mg/l + 
Myrtacine 
0.001%
Erythromycin 
1000 mg/l + 
Myrtacine 
0.0001%
Lo
g 
CF
U
 p
er
 w
el
l 
Sessile cells Planktonic cells**
**
*
** **
Fig. 7. Number of residual adherent and planktonic cells (log CFU per well; n = 3; mean ± SD) when Myrtacine ® and erythromycin are combined or not on a 48 h bioﬁlm 
after a 24 h contact according to the concentrations on (a) P. acnes CIP 53.117T (eryS/clindaS) and (b) P. acnes CIP 110.371 (eryR/clindaR) (static model). 
∗p < 0.05 ∗∗ p < 0.01. 
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outhors noted the low activity of erythromycin and clindamycin,
ven at high concentrations, of 0.5% and 1% (w/v) respectively. 
Myrtacine ® New Generation is a lipophilic extract of the leaves
f M. communis 6 times richer in myrtucommulones and ursolic
cid than the ethanolic extract Myrtacine ® ( Fiorini-Puybaret 2011 ).
hese active markers showed anti-inﬂammatory and antibacterial
. acnes activities ( Fiorini-Puybaret 2011 ). The batch ES120 used for
his study contained 8.07% (w/w) of myrtucommulones and in par-
icular 3.08% (w/w) of B’, 1.76% (w/w) of S, 3.25% (w/w) of isoS and
.32% (w/w) of A. 
The ﬁrst interest of Myrtacine ® New Generation is its antimi-
robial activity on P. acnes planktonic cells and also on bioﬁlms.
he antibacterial activity of traditional herbal medicines or ex-
racts, especially against P. acnes has already been demonstrated, as
ell as their anti-inﬂammatory effects ( Fu et al. 2012; Niyomkam
t al. 2010; Sharma et al. 2013 ). Myrtle ( M. communis ) is one of
he medicinal herbs found worldwide that is used against a large
umber of diseases, including skin diseases, because of its an-
ioxidant, antiviral, antibacterial and antifungal properties ( Alipour
t al. 2014; Fiorini-Puybaret 2011 ). Some of the main biologicallyctive components are described as antioxidant without antibac-
erial activity, like ursolic acid ( Sharma et al. 2013 ). Many other
ompounds are able to express antimicrobial activity, like limonene
nd, above all, myrtucommulones ( Fiorini-Puybaret 2011 ). These
atural acylphloroglucinols were described ﬁrst as antimicrobial
gents with low MICs against Gram-positive bacteria ( Appendino
t al. 2006 ) and, more recently, as anti-inﬂammatory molecules in
itro and in vivo ( Rossi et al. 2009 ). This is the ﬁrst report indicat-
ng that extract from M. communis was able to inhibit bioﬁlm for-
ation and reduce structured P. acnes bioﬁlm in a concentration
ange of 0.1% to 0.001% (w/v) ( i.e. 1000 to 10 mg/l), corresponding
o MIC values observed on planktonic cells ( Fiorini-Puybaret 2011 )
nd to the bactericidal concentrations obtained on planktonic cells
n a medium preventing planktonic growth (MBB). The effect ap-
ears to depend signiﬁcantly on concentration and contact time. A
oncentration of 0.01% reduces planktonic MBB population by 3 to
 log, and bioﬁlm population (static or dynamic model) after 48 h
f contact by 4 log. A partial disintegration of a 48 h bioﬁlm (dy-
amic model) was observed at this concentration from 1 to 5 min
f contact. 
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Fig. 8. Number of residual adherent and planktonic cells (log CFU per well; n = 2; mean ± SD) when Myrtacine ® and clindamycin are combined or not on a 48 h bioﬁlm 
after a 24 h contact according to the concentrations on (a) P. acnes CIP 53.117T (eryS/clindaS) and (b) P. acnes CIP 110.371 (eryR/clindaR) (static model). 
∗p < 0.05 ∗∗p < 0.01. 
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 The loss of susceptibility of microorganisms in the form of
bioﬁlm, including P. acnes , to the main antimicrobial agents or
treatments has a worldwide importance and, for this purpose
alone, Myrtacine ® New Generation can be considered as an orig-
inal antimicrobial agent. 
Considering this speciﬁc activity against P. acnes bioﬁlm and
the current antibiotic use in acne vulgaris treatment, the interest
of combining erythromycin (10 0 0 mg/l) or clindamycin (500 mg/l)
with Myrtacine ® New Generation was checked at concentrations
under the accepted active concentration i.e. 0.001% and 0.0001%
on a 48 h bioﬁlm (static model). In such conditions, the reduc-
tion of adherent and planktonic populations (released from the
bioﬁlm) is signiﬁcantly more important for the combinations than
for each compound alone. The addition of Myrtacine ® New Gener-
ation at 0.001% w/v (little or no activity alone) restores the sus-
ceptibility of erythromycin- or clindamycin-sensitive strains but,
more importantly, is effective against antibiotic-resistant strains.
In the latter case, the planktonic population released from the
bioﬁlm is not as dramatically reduced as for sensitive strains.
This highlights a marked improvement of the effect certainly
linked not only to a bioﬁlm deconstruction effect, with pop-
ulation return to planktonic status, but also to other mecha-
nisms and possibly multi-targets effects as other botanical prod-
ucts ( Gretsch. 2011; Radalovic et al. 2013 ) which need further
investigation. Ronclusion 
In conclusion, this is the ﬁrst demonstration of the activity of
 Myrtle extract, Myrtacine ® New Generation, as a preventive or
urative agent against P. acnes bioﬁlm and as a potent adjunc-
ive product eﬃcient during the antibiotic course for acne vul-
aris treatment. Considering the increasing percentages of P. acnes
trains resistant to erythromycin and clindamycin, the eﬃciency of
yrtle extract on P. acnes bioﬁlm alone or combined with antibi-
tics has to be considered to control P. acnes populations in acneic
atients. 
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